Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil

Psoriasis, a chronic, inflammatory skin disease, requires long-term therapy. Risankizumab is a humanized immunoglobulin G1 monoclonal antibody that specifically inhibits interleukin 23 by binding to its p19 subunit. The authors assessed the efficacy and safety of risankizumab compared with methotrex...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Anais brasileiros de dermatología 2024-12
Hauptverfasser:	Cestari, Tania F, Souza, Cacilda da Silva, Azulay-Abulafia, Luna, Romiti, Ricardo, Carvalho, André V E, Silva de Castro, Caio César, Marques, Silvio Alencar, Antonio, João Roberto, Fabrício, Lincoln, Soliman, Ahmed M, Wu, Tianshuang, Sinvhal, Ranjeeta, Stakias, Vassilis, Song, Alexandra P, Kalabic, Jasmina, Martin, Naomi, Oyafuso, Luiza Keiko Matsuka
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!